We write complex pharmaceutical documents with purpose-built AI.
We produce them up to 6× faster than a traditional consultancy, at a competitive price.
Subject-matter experts shouldn’t be writing and formatting templated documents. We allow their time to be spent on the science instead.
Our experts come from
Our in-house software handles the drafting, source-tracing and formatting. Senior reviewers who have performed actual submissions use it to generate your documents.
AcribaWord is our own editor. It reads your reports, the relevant guidelines, and any other relevant information. Then it produces a consistent submission-ready document which our reviewers can iterate on.
Our experts work inside AcribaWord to bring the document to submission quality. It runs QC on the reports for them, so their time goes to content and strategy, not formatting.
We delivered an IND update in thirty days: fifteen documents, including M2.4, M2.5 and M2.7 summaries written from scratch. The price was far below the nearest quote, which ran three months or more. Every page was reviewed by a former CSO who filed multiple INDs in the past.
Generic AI tools can’t ingest the inputs of a drug program. One program is dozens of reports and hundreds of pages, dense with tables and figures. And they can draft a simple document, but not the formatting and cross-referencing a regulatory or medical dossier requires.
Note: AcribaWord is also available as a standalone product. Enquire about licensing →
Request a walkthrough →We work with experts across most modalities and therapeutic areas. We have a partnership with CXO Swiss, a network of Swiss pharmaceutical leaders across clinical, regulatory, preclinical, CMC and finance.